Cystic fibrosis market forecast to reach $16.0bn by 2034 in the 7MM
Pipeline assets in development for CF draw attention to a limited range of MoAs.
Comment & Opinion
Insmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri
Morocco’s sweeping pharmaceutical pricing reform
ESC 2025: Higher leg muscle scores reduce cardiovascular risk independent of BMI
Four drugs race for first bispecific ADC approval
2024 saw growth recovery for almost all top biopharma companies
AI is improving idiopathic pulmonary fibrosis care
Infectious disease screening during substance use disorder treatment increases detection, prevention, and treatment
